Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

Lignende værker

• Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials
  af: Foley, Peter, et al.
  Udgivet: (2018)
• Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies
  af: Armstrong, April W., et al.
  Udgivet: (2018)
• A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial
  af: Blauvelt, A., et al.
  Udgivet: (2020)
• Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
  af: Kimball, A.B., et al.
  Udgivet: (2019)
• Guselkumab for plaque psoriasis
  Udgivet: (2019)